Wed, Mar 26, 11:32 AM (31 days ago)
**Summary of Precision BioSciences, Inc. (DTIL)** **Financial Performance:** - **Revenue:** Not provided. - **Net Income:** $7.2 million for the year ended December 31, 2024. - **Accumulated Deficit:** $482.5 million as of December 31, 2024. - **Cash and Cash Equivalents:** Expected to fund operating expenses and capital expenditure requirements into the second half of 2026. **Operating Expenses:** - Significant operating losses since inception. - Expects to continue incurring losses for the foreseeable future. - Substantial expenses incurred in connection with research and development activities and general and administrative costs. **Earnings Per Share (EPS):** Not explicitly provided. **Strategic Overview:** - Focused on improving life through genome editing. - Dedicated to translating the potential of genome editing into permanent genetic solutions for significant unmet medical needs. - Utilizing the ARCUS gene editing platform in genetic and infectious diseases. **Future Outlook:** - Expects to achieve first-in-human Phase 1 clinical data for two wholly-owned programs. - Plans to advance gene editing portfolio, including programs under development internally and with partners. - Strategic prioritization exercise ongoing to focus on complex edits and gene insertion. **Risk Factors:** - Significant competition in the biotechnology and pharmaceutical industries. - Dependence on the successful development and translation of ARCUS technology. - Risks associated with raising additional capital and requirements under current debt instruments. - Limited operating history and need for additional funding. - Dependence on key executives and attracting, retaining, and motivating qualified personnel. - Increased costs associated with operating as a public company. - Risks related to the identification, development, and commercialization of product candidates. - Regulatory landscape and requirements for product candidates. - Clinical trials and manufacturing challenges. - Dependence on collaborations and third-party relationships. - Risks related to intellectual property and proprietary information. - Risks related to data protection, privacy, and security. - Risks related to environmental, health, and safety laws and regulations. - Risks related to tax laws and regulations. **Financial Condition:** - Significant accumulated deficit and operating losses. - Dependence on collaborations and third-party funding. - Risks associated with raising additional capital and maintaining financial resources. **Market Position Changes:** - No significant changes in market position noted. - Focus on strategic prioritization and resource allocation. **Note:** The company has not commercialized any products and has never generated any revenue from product sales.